Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02)

References

• Ghia P, Ferreri AM, Caligaris-Cappio F. Chronic lymphocytic leucemia. Crit Rev Oncol Hematol 2007;64:234–246.
   PubMed Web of Science ®Google Scholar
• Johnson S, Smith AG, Loffler H, et al Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia: The French Cooperative Group on CLL. Lancet 1996;347:1432–1438.
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Robak T, Bloński JZ, Kasznicki M, et al Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723–2729.
   PubMed Web of Science ®Google Scholar
• Leporrier M, Chevret S, Cazin B, et al Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319–2325.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Lamanna N, Kay NE. Pentostatin treatment combinations in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2009;7:386–392.
   PubMedGoogle Scholar
• Huhn D, von Schilling C, Wilhelm M, et al Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326–1331.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, et al Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2153–2164.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, et al Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153–2164.
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E, et al Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800–809.
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U, et al German CLL Study Group. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115–3120.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, et al Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6–14.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL, et al Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49–53.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, et al Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070–4078.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, et al Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Karlsson KA, Strömberg M, Jönsson V, et al Caldribine (Cda) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as firstline treatment of symptomatic chronic lymphocytic leukemia (CLL). First results from the international randomized phase III trial. Blood 2007;110(Suppl. 1): (Abstract 630).
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Jamroziak K, et al Randomized comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide in untreated patients with chronic lymphocytic leukaemia: Report of the Polish Adult Leukemia Group (PALG-CLL3). Blood 2008;112(Suppl. 1): (Abstract 2103).
   Google Scholar
• Betticher DC, Ratschiller D, Hsu Schmitz SF, et al Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1998;9:721–726.
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Bloński JZ. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 2007;79:107–113.
   PubMed Web of Science ®Google Scholar
• Bertazzoni P, Laszlo D, Gigli F, et al Phase II trial of cladribine (2-CDA) and rituximab in patients with CLL and SLL: preliminary report of a single institution. J Clin Oncol 2007;25(18S): Abstract 7093.
   Google Scholar
• Esteve J, Villamor N, Colomer D, et al Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogenic transplantation and correlation with minimal residual disease status. Leukemia 2001;15:445–451.
   PubMed Web of Science ®Google Scholar
• Schetelig J, Thiede C, Bornhauser M, et al Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003;21:2747–2753.
   PubMedGoogle Scholar
• Sorror ML, Storer BE, Sandmaier BM, et al Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:4912–4920.
   PubMed Web of Science ®Google Scholar
• Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002;16:985–992.
   PubMed Web of Science ®Google Scholar
• Dreger Challet M. Autologous stem cell transplantation for chronic lymphocytic leukemia. Semin Hematol 2007;44:246–251.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Zahrieh D, Stephans K, et al Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005;106:4389–4396.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Schuller JC, Mayer M, Lanz D, et al A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials. Contemp Clin Trials 2009;30:201–204.
   PubMed Web of Science ®Google Scholar
• Hosing C, Saliba RM, Körbling M, et al High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:1290–1294.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Hallek M. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL). Best Pract Res Clin Haematol 2007;20:469–477.
   PubMed Web of Science ®Google Scholar
• Perea G, Sureda A, Martino R, et al Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001;80:592–597.
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Buss EC, Herrmann D, Goldschmidt H, Ho AD, Fruehauf S. Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy. Stem Cells 2003;21:568–574.
   PubMed Web of Science ®Google Scholar
• Tournilhac O, Cazin B, Leprètre S, et al Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004;103:363–365.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Moullet I, et al Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998;103:235–242.
   PubMed Web of Science ®Google Scholar
• Laszlo D, Galieni P, Raspadori D, et al Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma 2000;37:157–161.
   PubMed Web of Science ®Google Scholar
• Michallet M, Thiébaut A, Dreger P, et al Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000;108:595–601.
   PubMed Web of Science ®Google Scholar
• Lysak D, Koza V, Steinerova K, Jindra P, Vozobulova V, Schutzova M. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Ann Hematol 2005;84:456–461.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Itälä M, Siitonen T, et al Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. Bone Marrow Transplant 2008;41:239–244.
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Miqueleiz S, et al Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24:2337–2342.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM, et al Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1): (Abstract 325).
   Google Scholar
• Robak T, Moiseev SI, Dmoszynska A, et al Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH Trial. Blood 2008;112(Suppl. 1): (Abstract LBA-1).
   Google Scholar